Baird Medical Stock Price, News & Analysis

Baird Medical (NASDAQ: BDMD) announced completion of an advanced Microwave Ablation (MWA) training session on Dec. 8, 2025 led by Dr. Emad Kandil.

The program trained Dr. Richard Harding of Arizona Endocrine Surgery with observation of three live MWA procedures, a hands-on component, and strategic planning for integrating MWA into his Phoenix practice. Dr. Harding received a Certificate of Completion, underscoring proficiency in MWA and supporting expanded patient access to non‑surgical thyroid treatment options in Arizona.

Baird Medical (NASDAQ: BDMD) named Mark Saxton as Chief Executive Officer of its U.S. subsidiary effective December 3, 2025. Mr. Saxton has more than 25 years of commercial leadership in medical devices and will lead U.S. sales, marketing, and market development as Baird Medical accelerates U.S. entry for its microwave ablation (MWA) platform.

His prior roles include scaling VNUS Medical Technologies (doubling U.S. revenue from $49M to > $100M before a $512M acquisition by Covidien), supporting NeuroPace through a $117M IPO, and repositioning Ceterix for a $105M acquisition by Smith + Nephew.

Baird Medical (NASDAQ: BDMD) announced its official launch into the Egyptian market on Nov 3, 2025 with a successful first microwave bone ablation at Ain Shams Specialized Hospital.

The procedure, performed by Dr. Amr Mahmoud, treated a 1 x 1.5 cm bone lesion in a 30-year-old male with left thigh pain and achieved full ablation and marked pain relief, illustrating the Baird MWA system's use in musculoskeletal applications beyond soft tissue.

Baird Medical (NASDAQ: BDMD) announced clinical adoption of its Microwave Ablation (MWA) system at Elk Medical, a private endocrinology practice in Brooklyn, New York, on Oct. 27, 2025. Dr. Kazeem performed nine MWA procedures treating large thyroid nodules as a non-surgical alternative. The clinic reported that these initial procedures have been successfully reimbursed by Medicare, which the company described as an encouraging early step toward broader patient access and potential economic viability for MWA therapy in a key U.S. market.

Baird Medical (NASDAQ: BDMD) announced the company’s first successful microwave ablation (MWA) liver tumor procedure in Bangladesh on Oct 23, 2025. The treatment was performed at USB Hospital in Uttara, Dhaka, by Dr. Mofazzal Sharif Rasel and team on a 65-year-old patient with a 6 cm liver tumor, who is reported to be recovering well. The event represents a commercial and clinical adoption milestone for Baird Medical in South Asia and underscores the company’s stated focus on expanding global access to minimally invasive tumor therapies through strategic clinician and institution partnerships.

Baird Medical (NASDAQ: BDMD) participated in an International Thyroid Microwave Ablation Workshop at Hospital Canselor Tuanku Muhriz (HCTM), National University of Malaysia on October 1–2, 2025.

Led by Proctor Dr. Shuhang Xu, endocrinologist at Jiangsu Provincial Hospital, with HCTM surgeons Dr. Adi Syazni and Prof. Shahrun Niza, the two-day program combined theoretical lectures, complex case discussions, and hands-on training with mannequins and live patients to advance physician MWA skills and support global adoption of minimally invasive therapy.

Baird Medical (NASDAQ: BDMD) participated in a two-day Thyroid Microwave Ablation Workshop at Hospital Canselor Tuanku Muhriz, National University of Malaysia on Oct 1–2, 2025.

The immersive program combined lectures, complex case discussions and hands-on training with mannequins and live patient cases led by Proctor Dr. Shuhang Xu and HCTM faculty Dr. Adi Syazni and Prof. Shahrun Niza. Baird Medical supplied expertise and support to advance physician skills in minimally invasive Microwave Ablation (MWA) and to promote wider clinical adoption of MWA therapy in the region.

Baird Medical (NASDAQ: BDMD) participated in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism held in Beijing on October 17-18, 2025 at the China-Japan Friendship Hospital.

Chaired by Prof. Ming'an Yu, the workshop featured live procedures, clinical exchanges, and advanced technique discussions. Baird Medical said its presence highlights a commitment to international collaboration, sharing best practices for Microwave Ablation (MWA), and advancing minimally invasive thyroid care.

Baird Medical (NASDAQ: BDMD) announced its microwave ablation (MWA) system was successfully used in two minimally invasive procedures at UCSF Health on Oct 16, 2025.

Interventional radiologist Dr. Alexander Lam treated two patients with benign thyroid nodules measuring 5.0 cm and 6.5 cm, avoiding surgery. Active treatment time averaged less than 25 minutes per case; both patients remained comfortable under local anesthesia and reported minimal pain. The company said the cases demonstrate MWA as a non-surgical option that can preserve thyroid function and reduce surgical risks.